HTG Molecular Diagnostics Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on HTG Molecular Diagnostics's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
HTG Molecular Q2 GAAP loss per share widens, revenue down
Aug 11HTG Molecular Diagnostics amends senior loan facility
Jul 18Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?
Dec 10
Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?
Aug 27HTG Molecular completes product design lock for planned transcriptome panel
Jun 14These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat
Mar 26What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 20
HTG shares surge after upbeat 2020 revenue forecast
Jan 05HTG Molecular Diagnostics announced 1:15 reverse stock split
Nov 23HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow
Nov 18Revenue & Expenses Breakdown
How HTG Molecular Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 6 | -20 | 14 | 0 |
| 31 Dec 22 | 6 | -22 | 16 | 0 |
| 30 Sep 22 | 7 | -22 | 18 | 0 |
| 30 Jun 22 | 8 | -22 | 19 | 0 |
| 31 Mar 22 | 9 | -19 | 18 | 0 |
| 31 Dec 21 | 9 | -17 | 17 | 0 |
| 30 Sep 21 | 9 | -16 | 17 | 0 |
| 30 Jun 21 | 8 | -17 | 17 | 0 |
| 31 Mar 21 | 8 | -20 | 17 | 0 |
| 31 Dec 20 | 9 | -21 | 18 | 0 |
| 30 Sep 20 | 11 | -21 | 19 | 0 |
| 30 Jun 20 | 14 | -20 | 18 | 0 |
| 31 Mar 20 | 18 | -19 | 19 | 0 |
| 31 Dec 19 | 19 | -19 | 19 | 0 |
| 30 Sep 19 | 22 | -17 | 19 | 0 |
| 30 Jun 19 | 21 | -17 | 19 | 0 |
| 31 Mar 19 | 21 | -16 | 19 | 0 |
| 31 Dec 18 | 22 | -16 | 20 | 0 |
| 30 Sep 18 | 22 | -16 | 20 | 0 |
| 30 Jun 18 | 21 | -17 | 19 | 0 |
| 31 Mar 18 | 18 | -19 | 19 | 0 |
| 31 Dec 17 | 15 | -19 | 18 | 0 |
| 30 Sep 17 | 8 | -23 | 17 | 0 |
| 30 Jun 17 | 6 | -24 | 17 | 0 |
| 31 Mar 17 | 6 | -25 | 17 | 0 |
| 31 Dec 16 | 5 | -26 | 17 | 0 |
| 30 Sep 16 | 5 | -26 | 17 | 0 |
| 30 Jun 16 | 5 | -25 | 17 | 0 |
| 31 Mar 16 | 4 | -25 | 16 | 0 |
| 31 Dec 15 | 4 | -23 | 15 | 0 |
| 30 Sep 15 | 4 | -22 | 14 | 0 |
| 30 Jun 15 | 4 | -21 | 13 | 0 |
| 31 Mar 15 | 4 | -19 | 11 | 0 |
| 31 Dec 14 | 3 | -18 | 10 | 0 |
| 30 Sep 14 | 3 | -16 | 9 | 0 |
| 30 Jun 14 | 2 | -15 | 8 | 0 |
| 31 Mar 14 | 3 | -14 | 8 | 0 |
Quality Earnings: Insufficient data to determine if HTGM.Q has high quality earnings.
Growing Profit Margin: Insufficient data to determine if HTGM.Q's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HTGM.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare HTGM.Q's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if HTGM.Q's earnings growth over the past year exceeded the Healthcare Services industry average.
Return on Equity
High ROE: HTGM.Q has a negative Return on Equity (0%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 10:42 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HTG Molecular Diagnostics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |